First trimester PBMC microRNA predicts adverse pregnancy outcome

Area of Science:

• Reproductive biology
• Molecular diagnostics
• Biomarker discovery

Background:

• Adverse pregnancy outcomes like pre-eclampsia and miscarriage can be initiated early in gestation.
• Existing biomarkers for these conditions lack reliability in the first trimester.
• MicroRNAs, as cellular pathway regulators, present a novel avenue for early detection.

Purpose of the Study:

• To identify and validate maternal peripheral blood mononuclear cell (PBMC) microRNA markers for predicting adverse pregnancy outcomes.
• To assess the efficacy of these microRNA markers in early pregnancy detection of miscarriage and pre-eclampsia.

Main Methods:

• Investigated maternal PBMC microRNA markers through sequential experiments, selecting 30 candidates.
• Performed quantitative RT-PCR on 30 microRNAs from first-trimester samples of 39 patients (healthy, pre-eclampsia, miscarriage).
• Assessed predictive values and statistical significance of microRNA quantification results.

Main Results:

• Early first-trimester microRNA quantification predicted miscarriage (AUC=0.90) and late pre-eclampsia (AUC=0.90) with high statistical significance (P < 0.0001).
• Results were obtained at a mean of 34.9 ± 19.2 days post-implantation.
• Demonstrated a strong correlation between specific microRNA profiles and adverse pregnancy outcomes.

Conclusions:

• Maternal blood cell microRNA quantification provides a simple, interpretable early pregnancy test.
• This method is the first to reliably predict late pre-eclampsia in early pregnancy.
• Further research is needed to enhance the clinical utility of microRNA-based prediction of adverse pregnancy outcomes.